Guided Therapeutics Inc. (OTCMKTS:GTHP) Stock Short Interest Report for September

Guided Therapeutics Inc. (OTCMKTS:GTHP) saw a significant decrease in short interest in September. As of September 30th, there was short interest totaling 3,727 shares, a decrease of 45.4% from the September 15th total of 6,822 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 127,857 shares, the days-to-cover ratio is currently 0.0 days.

Guided Therapeutics Trading Up 5.6%

GTHP traded up $0.01 during trading on Thursday, hitting $0.19. The company’s stock had a trading volume of 601 shares, compared to its average volume of 20,757. Guided Therapeutics has a twelve month low of $0.15 and a twelve month high of $0.54. The business’s fifty day simple moving average is $0.24 and its 200 day simple moving average is $0.24. The firm has a market capitalization of $18.66 million, a price-to-earnings ratio of -4.75 and a beta of 0.70.

Guided Therapeutics (OTCMKTS:GTHP) last announced its earnings results on Thursday, August 13th. The company reported ($0.01) earnings per share for the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical technology company focused on developing diagnostic products for women’s health. The company’s primary focus has been the detection of cervical disease and cancer using minimally invasive or non-invasive technologies.

Its lead product, LuViva Advanced Cervical Scan, is designed to evaluate cervical tissue using optical spectroscopy. The system analyzes changes in tissue characteristics that may be associated with precancerous or cancerous conditions and is intended to help clinicians identify patients who may require additional evaluation, including biopsy.

Guided Therapeutics has pursued regulatory and commercial opportunities for its cervical disease detection technology in the United States and international markets.